公司資料
Pulmonx 股價、新聞與催化劑
- 股票代碼:
- LUNG
- 交易所:
- NASDAQ
- 產業:
- MedTech
- 所在地:
- United States
股票表現
2.23 USD (-7.85%)
收盤價
最後更新: 2026年8月17日
68M USD
市值
股價為何變動
As of Aug 17, 2026, LUNG closed down 7.85% at $2.23. No new same-company headline was identified in the current news window.
公司概覽
Minimally Invasive COPD Treatment
Pulmonx develops minimally invasive technologies for patients with severe emphysema and chronic obstructive pulmonary disease who remain highly symptomatic despite medical therapy.
Zephyr Endobronchial Valve
The Zephyr Valve is an implantable bronchoscopic device that occludes selected diseased lung regions, allowing healthier areas to function more effectively. It has FDA premarket approval, is available in more than 25 countries and is incorporated into treatment guidelines.
Patient Selection Tools
The Chartis Pulmonary Assessment System evaluates collateral ventilation to help determine whether a patient is suitable for valve therapy. StratX reports use CT imaging to characterize emphysema distribution and fissure completeness.
Digital Care Support
The LungTraX platform supports patient identification, referral and treatment workflow. Together with Zephyr, Chartis and StratX, it gives Pulmonx an integrated model spanning screening, procedural planning and therapy.
未來催化劑
- Pulmonx’s next three months are about Zephyr Valve adoption, new physician-site expansion, and continued lung-volume-reduction procedure growth. The company needs to keep proving that the minimally invasive COPD franchise can keep widening.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。